eISSN: 2299-0046
ISSN: 1642-395X
Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii
Current issue Archive Manuscripts accepted About the journal Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
Search
Editorial Policies
Sarajevo Declaration on Integrity and Visibility of Scholarly Publications
Share:
Send email
Share:
Review paper

The IL-23/Th17 pathway inhibitors in the treatment of psoriasis and the risk of skin malignancies: a review

Marta Krzysztofik
1
,
Paweł Brzewski
1, 2
,
Aleksandra Kulbat
3, 4
,
Magdalena Masajada
1, 2
,
Karolina Richter
2
,
Wojciech M. Wysocki
2, 3, 4

  1. Department of Dermatology and Venereology, Stefan Zeromski Municipal Hospital, Krakow, Poland
  2. Faculty of Medicine and Health Sciences, Andrzej Frycz Modrzewski Krakow University, Krakow, Poland
  3. Department of Oncological Surgery, 5th Military Clinical Hospital, Krakow, Poland
  4. National Institute of Oncology, Maria Sklodowska-Curie Memorial, Warsaw, Poland
Adv Dermatol Allergol
DOI: https://doi.org/10.5114/ada.2024.143428
Online publish date: 2024/10/04
Article file
- The IL-23.pdf  [0.18 MB]
Get citation
 
 
1. Boehncke WH, Schön MP. Psoriasis. Lancet 2015; 386: 983-94.
2. Alinaghi F, Calov M, Kristensen LE, et al. Prevalence of psoriatic arthritis in patients with psoriasis: a systematic review and meta-analysis of observational and clinical studies. J Am Acad Dermatol 2019; 80: 251-65.e19.
3. Pathirana D, Ormerod A, Saiag P, et al. European S3-guidelines on the systemic treatment of psoriasis vulgaris. J Eur Acad Dermatol Venereol 2009; 23 Suppl 2: 1-70.
4. Detmar M, Orfanos CE. Tumor necrosis factor-alpha inhibits cell proliferation and induces class II antigens and cell adhesion molecules in cultured normal human keratinocytes in vitro. Arch Dermatol Res 1990; 282: 238-45.
5. Austin LM, Ozawa M, Kikuchi T, et al. The majority of epidermal t cells in psoriasis vulgaris lesions can produce type 1 cytokines, interferon-g, interleukin-2, and tumor necrosis factor-a, defining TC1 (cytotoxic T lymphocyte) and TH1 effector populations:1 a type 1 differentiation bias is also measured in circulating blood T cells in psoriatic patients. J Investig Dermatol 1999; 113: 752-9.
6. Chiricozzi A, Suárez-Fariñas M, Fuentes-Duculan J, et al. Increased expression of interleukin-17 pathway genes in nonlesional skin of moderate‐to‐severe psoriasis vulgaris. Br J Dermatol 2016; 174: 136-45.
7. Brembilla NC, Senra L, Boehncke W-H. The IL-17 family of cytokines in psoriasis: IL-17A and beyond. Front Immunol 2018; 9: 1682.
8. Yang K, Oak ASW, Elewski BE. Use of IL-23 inhibitors for the treatment of plaque psoriasis and psoriatic arthritis: a comprehensive review. Am J Clin Dermatol 2021; 22: 173-92.
9. Teng MWL, Bowman EP, McElwee JJ, et al. IL-12 and IL-23 cytokines: from discovery to targeted therapies for immune-mediated inflammatory diseases. Nat Med 2015; 21: 719-29.
10. Polesie S, Gillstedt M, Sönnergren HH, et al. Methotrexate treatment and risk for cutaneous malignant melanoma: a retrospective comparative registry-based cohort study.
11. Br J Dermatol 2017; 176: 1492-9.
12. Stern RS. The risk of melanoma in association with long-term exposure to PUVA. J Am Acad Dermatol 2001; 44: 755-61.
13. Esse S, Mason KJ, Green AC, Warren RB. Melanoma risk in patients treated with biologic therapy for common inflammatory diseases. JAMA Dermatol 2020; 156: 787-94.
14. Liu R, Wan Q, Zhao R, et al. Risk of non-melanoma skin cancer with biological therapy in common inflammatory diseases: a systemic review and meta-analysis. Cancer Cell Int 2021; 21: 614.
15. Krzysztofik M, Brzewski P, Cuber P, et al. Risk of melanoma and non-melanoma skin cancer in patients with psoriasis and psoriatic arthritis treated with targeted therapies: a systematic review and meta-analysis. Pharmaceuticals 2023; 17: 14.
16. Vignali DAA, Kuchroo VK. IL-12 family cytokines: immunological playmakers. Nat Immunol 2012; 13: 722-8.
17. Teng MWL, Bowman EP, McElwee JJ, et al. IL-12 and IL-23 cytokines: from discovery to targeted therapies for immune-mediated inflammatory diseases. Nat Med 2015; 21: 719-29.
18. Subhadarshani S, Yusuf N, Elmets CA. IL-23 and the tumor microenvironment. Adv Exp med Biol 2021; 1290: 89-98.
19. Tugues S, Burkhard SH, Ohs I, et al. New insights into IL-12-mediated tumor suppression. Cell Death Differ 2015; 22: 237-46.
20. Nastala CL, Edington HD, McKinney TG, et al. Recombinant IL-12 administration induces tumor regression in association with IFN-gamma production. J Immunol 1994; 153: 1697-706.
21. Noguchi Y, Jungbluth A, Richards EC, Old LJ. Effect of interleukin 12 on tumor induction by 3-methylcholanthrene. Proc Natl Acad Sci 1996; 93: 11798-801.
22. Colombo MP, Trinchieri G. Interleukin-12 in anti-tumor immunity and immunotherapy. Cytokine Growth Factor Rev 2002; 13: 155-68.
23. Eisenring M, vom Berg J, Kristiansen G, et al. IL-12 initiates tumor rejection via lymphoid tissue-inducer cells bearing the natural cytotoxicity receptor NKp46. Nat Immunol 2010; 11: 1030-8.
24. Langowski JL, Zhang X, Wu L, et al. IL-23 promotes tumour incidence and growth. Nature 2006; 442: 461-5.
25. Teng MWL, Andrews DM, McLaughlin N, et al. IL-23 suppresses innate immune response independently of IL-17A during carcinogenesis and metastasis. Proc Natl Acad Sci 2010; 107: 8328-33.
26. Schwarz A, Ständer S, Berneburg M, et al. Interleukin-12 suppresses ultraviolet radiation-induced apoptosis by inducing DNA repair. Nat Cell Biol 2002; 4: 26-31.
27. Schwarz A, Grabbe S, Aragane Y, et al. Interleukin-12 prevents ultraviolet b-induced local immunosuppression and overcomes UVB-induced tolerance. J Investig Dermatol 1996; 106: 1187-91.
28. Meeran SM, Mantena SK, Elmets CA, Katiyar SK. (-)-epigallocatechin-3-gallate prevents photocarcinogenesis in mice through interleukin-12-dependent DNA repair. Cancer Res 2006; 66: 5512-20.
29. Majewski S, Jantschitsch C, Maeda A, et al. IL-23 antagonizes UVR-induced immunosuppression through two mechanisms: reduction of UVR-induced DNA damage and inhibition of UVR-induced regulatory T cells. J Investig Dermatol 2010; 130: 554-62.
30. Kortylewski M, Xin H, Kujawski M, et al. Regulation of the IL-23 and IL-12 balance by Stat3 signaling in the tumor microenvironment. Cancer Cell 2009; 15: 114-23.
31. Nasti TH, Cochran JB, Vachhani RV, et al. IL-23 inhibits melanoma development by augmenting DNA repair and modulating T cell subpopulations. J Immunol 2017; 198: 950-61.
32. Overwijk WW, de Visser KE, Tirion FH, et al. Immunological and antitumor effects of IL-23 as a cancer vaccine adjuvant. J Immunol 2006; 176: 5213-22.
33. Fang S, Wang Y, Chun YS, et al. The relationship between blood IL-12p40 level and melanoma progression. Int J Cancer 2015; 136: 1874-80.
34. Kimball AB, Papp KA, Wasfi Y, et al. Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis treated for up to 5 years in the PHOENIX 1 study. J Eur Acad Dermatol Venereol 2013; 27: 1535-45.
35. Langley RG, Lebwohl M, Krueger GG, et al. Long-term efficacy and safety of ustekinumab, with and without dosing adjustment, in patients with moderate-to-severe psoriasis: results from the PHOENIX 2 study through 5 years of follow-up. Br J Dermatol 2015; 172: 1371-83.
36. Hu W, Fang L, Ni R, et al. Changing trends in the disease burden of non-melanoma skin cancer globally from 1990 to 2019 and its predicted level in 25 years. BMC Cancer 2022; 22: 836.
37. Yang K, Oak ASW, Elewski BE. Use of IL-23 inhibitors for the treatment of plaque psoriasis and psoriatic arthritis: a comprehensive review. Am J Clin Dermatol 2021; 22: 173-92.
38. Blauvelt A, Lebwohl M, Langley RG, et al. Malignancy rates through 5 years of follow-up in patients with moderate-to-severe psoriasis treated with guselkumab: pooled results from the VOYAGE 1 and VOYAGE 2 trials. J Am Acad Dermatol 2023; 89: 274-82.
39. Thaci D, Piaserico S, Warren RB, et al. Five-year efficacy and safety of tildrakizumab in patients with moderate-to-severe psoriasis who respond at week 28: pooled analyses of two randomized phase III clinical trials (ReSURFACE 1 and ReSURFACE 2)*. Br J Dermatol 2021; 185: 323-34.
40. Papp KA, Blauvelt A, Puig L, et al. Long-term safety and efficacy of risankizumab for the treatment of moderate-to-severe plaque psoriasis: interim analysis of the LIMMitless Open-Label Extension Trial up to 5 years of follow-up. J Am Acad Dermatol 2023; 89: 1149-58.
41. Centers for Disease Control and Prevention United States Cancer Statistics: Incidence of Malignant Melanoma of the Skin – United States, 2009-2018. USCS Data Brief, no. 28. Atlanta.
42. Kridin K, Abdelghaffar M, Mruwat N, et al. Are interleukin 17 and interleukin 23 inhibitors associated with malignancies? Insights from an international population-based study. J Eur Acad Dermatol Venereol 2024; 38: 315-24.
43. Gaffen SL. Recent advances in the IL-17 cytokine family. Curr Opin Immunol 2011; 23: 613-9.
44. Brembilla NC, Senra L, Boehncke WH. The IL-17 family of cytokines in psoriasis: IL-17A and beyond. Front Immunol 2018; 9: 1682.
45. Dong C. Th17 cells in development: an updated view of their molecular identity and genetic programming. Nat Rev Immunol 2008; 8: 337-48.
46. Amatya N, Garg AV, Gaffen SL. IL-17 signaling: the yin and the yang. Trends Immunol 2017; 38: 310-22.
47. Awane M, Andres PG, Li DJ, Reinecker HC. NF-Kappa B-inducing kinase is a common mediator of IL-17-, TNF-alpha-, and IL-1 beta-induced chemokine promoter activation in intestinal epithelial cells. J Immunol 1999; 162: 5337-44.
48. Onishi RM, Gaffen SL. Interleukin-17 and its target genes: mechanisms of interleukin-17 function in disease. Immunology 2010; 129: 311-21.
49. Murugaiyan G, Saha B. Protumor vs antitumor functions of IL-17. J Immunol 2009; 183: 4169-75.
50. Numasaki M, Watanabe M, Suzuki T, et al. IL-17 enhances the net angiogenic activity and in vivo growth of human non-small cell lung cancer in SCID mice through promoting CXCR-2-dependent angiogenesis. J Immunol 2005; 175: 6177-89.
51. Numasaki M. Interleukin-17 promotes angiogenesis and tumor growth. Blood 2003; 101: 2620-7.
52. Numasaki M, Lotze MT, Sasaki H. Interleukin-17 augments tumor necrosis factor-a-induced elaboration of proangiogenic factors from fibroblasts. Immunol Lett 2004; 93: 39-43.
53. Honorati MC, Neri S, Cattini L, Facchini A. Interleukin-17, a regulator of angiogenic factor release by synovial fibroblasts. Osteoarthritis Cartilage 2006; 14: 345-52.
54. De Simone V, Franzè E, Ronchetti G, et al. Th17-type cytokines, IL-6 and TNF-a synergistically activate STAT3 and NF-KB to promote colorectal cancer cell growth. Oncogene 2015; 34: 3493-503.
55. Jain P, Javdan M, Feger FK, et al. Th17 and non-Th17 interleukin-17-expressing cells in chronic lymphocytic leukemia: delineation, distribution, and clinical relevance. Haematologica 2012; 97: 599-607.
56. Lu L, Pan K, Zheng HX, et al. IL-17A promotes immune cell recruitment in human esophageal cancers and the infiltrating dendritic cells represent a positive prognostic marker for patient survival. J Immunother 2013; 36: 451-8.
57. Tong Z, Yang XO, Yan H, et al. A protective role by interleukin-17F in colon tumorigenesis. PLoS One 2012; 7: e34959.
58. Martin-Orozco N, Muranski P, Chung Y, et al. T helper 17 cells promote cytotoxic t cell activation in tumor immunity. Immunity 2009; 31: 787-98.
59. Muranski P, Boni A, Antony PA, et al. Tumor-specific Th17-polarized cells eradicate large established melanoma. Blood 2008; 112: 362-73.
60. Rodriguez C, Araujo Furlan CL, Tosello Boari J, et al. Interleukin-17 signaling influences CD8+ T cell immunity and tumor progression according to the IL-17 receptor subunit expression pattern in cancer cells. Oncoimmunology 2023; 12: 2261326.
61. Nuñez S, Saez JJ, Fernandez D, et al. T helper type 17 cells contribute to anti-tumour immunity and promote the recruitment of T helper type 1 cells to the tumour. Immunology 2013; 139: 61-71.
62. Chen YS, Huang TH, Liu CL, et al. Locally targeting the IL-17/IL-17RA axis reduced tumor growth in a murine B16F10 melanoma model. Hum Gene Ther 2019; 30: 273-85.
63. Wang L, Yi T, Kortylewski M, et al. IL-17 can promote tumor growth through an IL-6-Stat3 signaling pathway. J Exp Med 2009; 206: 1457-64.
64. Tang Q, Li J, Zhu H, et al. Hmgb1-IL-23-IL-17-IL-6-Stat3 axis promotes tumor growth in murine models of melanoma. Mediators Inflamm 2013; 2013: 713859.
65. Tosi A, Nardinocchi L, Carbone ML, et al. Reduced interleukin-17-expressing cells in cutaneous melanoma. Biomedicines 2021; 9: 1930.
66. Yan BY, Garcet S, Gulati N, et al. Novel immune signatures associated with dysplastic naevi and primary cutaneous melanoma in human skin. Exp Dermatol 2019; 28: 35-44.
67. Nardinocchi L, Sonego G, Passarelli F, et al. Interleukin-17 and interleukin-22 promote tumor progression in human nonmelanoma skin cancer. Eur J Immunol 2015; 45: 922-31.
68. Wu L, Chen X, Zhao J, et al. A novel IL-17 signaling pathway controlling keratinocyte proliferation and tumorigenesis via the TRAF4-ERK5 axis. J Exp Med 2015; 212: 1571-87.
69. Tuong ZK, Lewandowski A, Bridge JA, et al. Cytokine/chemokine profiles in squamous cell carcinoma correlate with precancerous and cancerous disease stage. Sci Rep 2019; 9: 17754.
70. Gasparoto TH, de Oliveira CE, de Freitas LT, et al. Inflammatory events during murine squamous cell carcinoma development. J Inflamm 2012; 9: 46.
71. Pellegrini C, Orlandi A, Costanza G, et al. Expression of IL-23/Th17-related cytokines in basal cell carcinoma and in the response to medical treatments. PLoS One 2017; 12: e0183415.
72. Hawkes JE, Yan BY, Chan TC, Krueger JG. Discovery of the IL-23/IL-17 signaling pathway and the treatment of psoriasis. J Immunol 2018; 201: 1605-13.
73. McInnes IB, Mease PJ, Ritchlin CT, et al. Secukinumab sustains improvement in signs and symptoms of psoriatic arthritis: 2 year results from the phase 3 FUTURE 2 study. Rheumatology 2017; 56: 1993-2003.
74. Smith SD, Stratigos A, Augustin M, et al. Integrated safety analysis on skin cancers among patients with psoriasis receiving ixekizumab in clinical trials. Dermatol Ther (Heidelb) 2023; 13: 1773-87.
75. Gottlieb A, Lebwohl M, Liu C, et al. Malignancy rates in brodalumab clinical studies for psoriasis. Am J Clin Dermatol 2020; 21: 421-30.
76. Ritchlin CT, Coates LC, McInnes IB, et al. Bimekizumab treatment in biologic DMARD-naïve patients with active psoriatic arthritis: 52-week efficacy and safety results from the phase III, randomised, placebo-controlled, active reference BE OPTIMAL study. Ann Rheum Dis 2023; 82: 1404-14.
Copyright: © 2024 Termedia Sp. z o. o. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (http://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
FEATURED PRODUCTS
BOOKS
• Atopowe Zapalenie Skóry • Choroby alergiczne w praktyce lekarza rodzinnego • Alergologia – kompendium
Termedia
About us Contact
Copyright notice Privacy policy Advertising policy Contact us
Quick links
Journals Books eBooks Events
© 2024 Termedia Sp. z o.o.
Developed by Bentus.